Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)

PURPOSE: Management of progressive, metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has been a great challenge due to its poor prognosis and limited treatment options. Recently, apatinib, an orally anti-angiogenic tyrosine kinase inhibitor (TKI) is reported to be us...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liang, You, Qinqin, Wang, Jun, Wang, Hanjin, Li, Shaohua, Tian, Rui, Yao, Xiaocheng, Wu, Wenyu, Zhang, Lele, Wang, Feng, Lin, Yansong, Li, Shuren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474580/
https://www.ncbi.nlm.nih.gov/pubmed/35767182
http://dx.doi.org/10.1007/s12020-022-03113-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474580/
https://www.ncbi.nlm.nih.gov/pubmed/35767182
http://dx.doi.org/10.1007/s12020-022-03113-9

Ejemplares similares